Incidence of pneumococcal disease from 2003 to 2019 in children ≤17 years in England.
Invasive pneumococcal disease
Pneumococcal conjugate vaccine
Pneumococcal disease
Pneumococcal pneumonia
United Kingdom
Journal
Pneumonia (Nathan Qld.)
ISSN: 2200-6133
Titre abrégé: Pneumonia (Nathan)
Pays: England
ID NLM: 101663459
Informations de publication
Date de publication:
23 Jan 2023
23 Jan 2023
Historique:
received:
08
08
2022
accepted:
15
12
2022
entrez:
22
1
2023
pubmed:
23
1
2023
medline:
23
1
2023
Statut:
epublish
Résumé
Pneumococcal disease is a leading cause of communicable disease morbidity and mortality globally. We aimed to estimate invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and all-cause pneumonia (ACP) incidence rates (IRs) in children aged 0-17 years in England from 2003 to 2019. A retrospective study in children ≤17 years old from 2003 to 2019 using the Clinical Practice Research Datalink (CPRD) Gold and Hospital Episodes Statistics Admitted Patient Care (HES APC) databases. IPD episodes were identified in hospital records (HES APC). PP (caused by Streptococcus pneumoniae only) and ACP episodes (caused by any pathogen) were identified in primary care (CPRD) and in hospital records (HES APC). Annual IRs by age-group were calculated as the number of episodes/person-years (PY) at risk, with 95% confidence intervals (95% CI). Interrupted time series analyses were conducted to assess changes in IRs across the post-PCV7 (2007-2009), early post-PCV13 (2011-2014) and late post-PCV13 (2015-2019) periods compared to the pre-PCV7 period (2003-2005) using generalized linear models. 170 IPD episodes, 769 PP episodes and 12,142 ACP episodes were identified in 1,500,686 children in 2003-2019. The overall IPD, PP and ACP IRs (per 100,000 PY) were 2.29 (95% CI 1.96-2.66), 10.34 (95% CI 9.62-11.10) and 163.37 (95% CI 160.47-166.30), respectively. The highest IPD, PP and ACP IRs were observed in children aged < 2 years compared to older children (2-4 and 5-17 years). IPD IRs decreased between the pre-PCV7 period and the late post-PCV13 period from 3.28 (95% CI 2.42-4.33) to 1.41 (95% CI 0.80-2.29), IRR 0.28 (95% CI 0.09-0.90), p-value 0.033. PP IRs declined between the pre-PCV7 period and the late post-PCV13 period from 14.65 (95% CI 12.77-16.72) to 3.87 (95% CI 2.81-5.20), IRR 0.19 (95% CI 0.09-0.38), p-value < 0.001. ACP IRs declined between the pre-PCV7 period and the late post-PCV13 period from 167.28 (95% CI 160.78-173.96) to 124.96 (95% CI 118.54-131.63), IRR 0.77 (95% CI 0.66-0.88), p-value < 0.001. The clinical burden of IPD, PP and ACP declined in children in England aged 0-17 years between 2003 and 2019, especially in the late post-PCV13 period. This study highlights the importance of PCV vaccination in reducing the burden of PD and ACP in children in England.
Sections du résumé
BACKGROUND
BACKGROUND
Pneumococcal disease is a leading cause of communicable disease morbidity and mortality globally. We aimed to estimate invasive pneumococcal disease (IPD), pneumococcal pneumonia (PP) and all-cause pneumonia (ACP) incidence rates (IRs) in children aged 0-17 years in England from 2003 to 2019.
METHODS
METHODS
A retrospective study in children ≤17 years old from 2003 to 2019 using the Clinical Practice Research Datalink (CPRD) Gold and Hospital Episodes Statistics Admitted Patient Care (HES APC) databases. IPD episodes were identified in hospital records (HES APC). PP (caused by Streptococcus pneumoniae only) and ACP episodes (caused by any pathogen) were identified in primary care (CPRD) and in hospital records (HES APC). Annual IRs by age-group were calculated as the number of episodes/person-years (PY) at risk, with 95% confidence intervals (95% CI). Interrupted time series analyses were conducted to assess changes in IRs across the post-PCV7 (2007-2009), early post-PCV13 (2011-2014) and late post-PCV13 (2015-2019) periods compared to the pre-PCV7 period (2003-2005) using generalized linear models.
RESULTS
RESULTS
170 IPD episodes, 769 PP episodes and 12,142 ACP episodes were identified in 1,500,686 children in 2003-2019. The overall IPD, PP and ACP IRs (per 100,000 PY) were 2.29 (95% CI 1.96-2.66), 10.34 (95% CI 9.62-11.10) and 163.37 (95% CI 160.47-166.30), respectively. The highest IPD, PP and ACP IRs were observed in children aged < 2 years compared to older children (2-4 and 5-17 years). IPD IRs decreased between the pre-PCV7 period and the late post-PCV13 period from 3.28 (95% CI 2.42-4.33) to 1.41 (95% CI 0.80-2.29), IRR 0.28 (95% CI 0.09-0.90), p-value 0.033. PP IRs declined between the pre-PCV7 period and the late post-PCV13 period from 14.65 (95% CI 12.77-16.72) to 3.87 (95% CI 2.81-5.20), IRR 0.19 (95% CI 0.09-0.38), p-value < 0.001. ACP IRs declined between the pre-PCV7 period and the late post-PCV13 period from 167.28 (95% CI 160.78-173.96) to 124.96 (95% CI 118.54-131.63), IRR 0.77 (95% CI 0.66-0.88), p-value < 0.001.
CONCLUSIONS
CONCLUSIONS
The clinical burden of IPD, PP and ACP declined in children in England aged 0-17 years between 2003 and 2019, especially in the late post-PCV13 period. This study highlights the importance of PCV vaccination in reducing the burden of PD and ACP in children in England.
Identifiants
pubmed: 36683061
doi: 10.1186/s41479-022-00103-3
pii: 10.1186/s41479-022-00103-3
pmc: PMC9868000
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2Informations de copyright
© 2023. Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
Références
Int J Infect Dis. 2020 Apr;93:146-150
pubmed: 31982620
Respir Med. 2003 Nov;97(11):1219-24
pubmed: 14635977
Clin Infect Dis. 2019 Jun 18;69(1):84-90
pubmed: 30281069
BMC Med. 2018 Feb 8;16(1):13
pubmed: 29415741
BMJ Open. 2020 Jun 22;10(6):e038767
pubmed: 32571866
Pharmacoepidemiol Drug Saf. 2019 Jun;28(6):821-829
pubmed: 30993835
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
Pediatr Res. 2022 Oct;92(4):1161-1167
pubmed: 34937875
Acta Paediatr. 2018 Mar 25;:
pubmed: 29577411
Lancet Infect Dis. 2015 May;15(5):535-43
pubmed: 25801458
Emerg Infect Dis. 2019 Sep;25(9):1708-1718
pubmed: 31441745
Lancet Infect Dis. 2018 Apr;18(4):441-451
pubmed: 29395999
Epidemiol Infect. 2019 Sep 09;147:e263
pubmed: 31496464
Lancet Child Adolesc Health. 2020 Jun;4(6):425-434
pubmed: 32450122
J Med Econ. 2021 Jan-Dec;24(1):1098-1107
pubmed: 34461796
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
Pragmat Obs Res. 2019 Sep 23;10:53-65
pubmed: 31576189
J Infect. 2015 Oct;71(4):428-36
pubmed: 26159503
Paediatr Perinat Epidemiol. 2020 Mar;34(2):150-160
pubmed: 32010997
Vaccine. 2019 Jan 3;37(1):41-48
pubmed: 30478004
Int J Epidemiol. 2017 Aug 1;46(4):1093-1093i
pubmed: 28338941
BMJ. 2009 Dec 10;339:b5213
pubmed: 20007665